Meeting
2018 ASCO Annual Meeting
A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET co-expressing metastatic pancreatic adenocarcinoma.
Authors
Olumide B. Gbolahan
Indiana University School of Medicine, Indianapolis, IN
Olumide B. Gbolahan , Amikar Sehdev , Safi Shahda , Susan Perkins , Murray Korc , Patrick J. Loehrer Sr., Bert H. O'Neil
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT03213626
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS4157)
DOI
10.1200/JCO.2018.36.15_suppl.TPS4157
Abstract #
TPS4157
Poster Bd #
333a
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC).
First Author: Dirk Strumberg
Poster
2013 Gastrointestinal Cancers Symposium
Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer.
First Author: Katherine Fan
Poster
2012 ASCO Annual Meeting
Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).
First Author: Beth A. Hellerstedt
